Step 1 topics → Endocrine → Thyroid Pharmacotherapy (Levothyroxine, Methimazole, PTU, Iodine)

Thyroid Pharmacotherapy (Levothyroxine, Methimazole, PTU, Iodine)

USMLE Step 1 trap: Confuses trimester-specific antithyroid drug preference: PTU in first trimester (teratogenicity of methimazole), methimazole thereafter (hepatotoxicity of PTU). PTU is preferred in the first trimester because methimazole is associated with aplasia cutis and choanal atresia; methimazole is preferred in the second and third trimesters due to PTU's hepatotoxicity risk.

Thyroid pharmacotherapy shows up on USMLE Step 1 as both a pure pharmacology topic and as the management layer on top of hyperthyroid and hypothyroid pathology questions. You need to know not just what each drug does, but when to use which one — and that's where most students trip up. The exam loves trimester-specific drug choices, the distinction between methimazole and PTU mechanisms, and the adverse effect profiles that require immediate action.

The tricky part isn't memorizing the drugs — it's the clinical decision points. Should this pregnant patient get methimazole or PTU? Why is PTU preferred in thyroid storm but not for long-term management? What do you tell every patient starting an antithyroid drug about fever and sore throat? These are the application-level questions USMLE Step 1 favors, and they require you to understand the reasoning, not just the list.

The biggest conceptual traps here involve incomplete mental models: students think methimazole and PTU are interchangeable, or that radioiodine is only off-limits in pregnancy. The exam will build a vignette that punishes exactly those assumptions — a patient with Graves' ophthalmopathy getting radioiodine, or a first-trimester patient given methimazole. If you can explain the reasoning behind each drug choice, you'll handle any variation the exam throws at you.

From real student decks
81%have cards covering this topic
78%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Methimazole is the preferred antithyroid drug throughout pregnancy.
Right: PTU is preferred in the first trimester because methimazole is associated with aplasia cutis and choanal atresia; methimazole is preferred in the second and third trimesters due to PTU's hepatotoxicity risk.
Methimazole is actually the preferred antithyroid drug outside of pregnancy, but the first trimester is a critical exception. Methimazole carries a teratogenic risk — specifically aplasia cutis (absent skin patches on the scalp) and choanal atresia — making it unsafe in early organogenesis. PTU takes over in the first trimester, but it isn't perfect either: it carries significant hepatotoxicity risk, so the approach switches back to methimazole in the second and third trimesters once organogenesis is complete. The key mental model is trimester-specific, not one drug for all of pregnancy.
Common mistake
Wrong: Methimazole and PTU have identical mechanisms of action.
Right: Both block thyroid peroxidase, but PTU additionally inhibits peripheral conversion of T4 to T3 by blocking deiodinase, making it preferred in thyroid storm.
Both methimazole and PTU block thyroid peroxidase, which prevents new hormone synthesis — but that's where their similarity ends. PTU has a second mechanism: it inhibits type 1 deiodinase, blocking the peripheral conversion of T4 (the storage form) to T3 (the active form). In thyroid storm, circulating T4 is being rapidly converted to T3 and causing the crisis, so blocking that conversion gives PTU a meaningful acute advantage. Methimazole has no effect on peripheral conversion, which is why PTU is the preferred agent in thyroid storm despite methimazole being preferred in most other contexts.
Common mistake
Gap: Misses that agranulocytosis is a shared, serious adverse effect of both antithyroid drugs requiring immediate discontinuation
Both methimazole and PTU can cause agranulocytosis; patients should be instructed to stop the drug and seek evaluation immediately if they develop fever or sore throat.
Agranulocytosis is not unique to one antithyroid drug — it's a rare but serious risk with both methimazole and PTU. The mechanism is idiosyncratic (not dose-dependent), so it can occur at any point during treatment. Every patient starting either drug needs explicit counseling: if they develop fever, sore throat, or mouth sores, they must stop the drug immediately and get a CBC to check for neutropenia. This is a classic 'what do you tell the patient' setup on Step 1, and the answer is the same regardless of which drug they're on.
Common mistake
Wrong: Radioiodine (131-I) is contraindicated only in pregnancy.
Right: Radioiodine is contraindicated in pregnancy and breastfeeding, and is relatively contraindicated in Graves' ophthalmopathy because it can worsen eye disease.
Pregnancy is the absolute contraindication to radioiodine that most students know, but the exam tests further. Breastfeeding is also an absolute contraindication because 131-I concentrates in breast tissue and can be transferred to the infant. Beyond that, active Graves' ophthalmopathy is a relative contraindication — radioiodine triggers a TSH-receptor antibody surge that can worsen the inflammatory eye disease. A patient with significant proptosis or eye findings should not receive radioiodine without very careful consideration, and the exam will present exactly this scenario to see if you know the distinction.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Levothyroxine pharmacokinetics: how long it takes TSH to equilibrate after a dose change, why T4 (not T3) is given, and how to interpret TSH levels when monitoring thyroid replacement therapy.
  2. The mechanistic difference between methimazole and PTU — both block thyroid peroxidase, but PTU alone blocks peripheral conversion of T4 to T3 — and why that extra mechanism makes PTU the drug of choice in thyroid storm.
  3. Trimester-specific antithyroid drug selection: PTU in the first trimester (methimazole teratogenicity: aplasia cutis, choanal atresia), switch to methimazole in second and third trimesters (PTU hepatotoxicity risk).
  4. Shared adverse effects of antithyroid drugs — especially agranulocytosis — and the clinical instruction that fever or sore throat requires immediate drug discontinuation and CBC.
  5. Radioiodine (131-I) indications, absolute contraindications (pregnancy, breastfeeding), and relative contraindications including active Graves' ophthalmopathy due to risk of worsening eye disease.

Can you avoid these mistakes?

A 28-year-old woman at 8 weeks gestation is diagnosed with Graves' disease and needs antithyroid therapy. Which drug do you choose, and why? What would change if she were 20 weeks pregnant?
A patient with Graves' disease is in thyroid storm in the ICU. You're choosing between methimazole and PTU — which do you choose, and what is the mechanistic reason for that choice that goes beyond just 'blocking thyroid peroxidase'?
A patient on methimazole for 3 months calls to report a fever and sore throat for the past 2 days. What is the most important next step, and what life-threatening complication are you concerned about? Does your answer change if the patient were on PTU instead?
A 45-year-old woman with Graves' disease and significant bilateral proptosis is asking about treatment options. Her endocrinologist is considering radioiodine. What contraindication or relative contraindication should be raised, and why does radioiodine pose a specific risk in this patient?

Related topics

Graves Disease Hypothyroidism (Primary, Cretinism, Drug-Induced) Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →